Clinical trials located in

Burgos

Burgos city is located in Spain. Currently, 11 clinical trials are being conducted in this city.

Burgos, located in northern Spain, is renowned for its medieval architecture, notably the Burgos Cathedral, a UNESCO World Heritage Site. Founded in 884, the city played a pivotal role in the Spanish Reconquista. It’s also famous for being the birthplace of El Cid, the 11th-century Castilian nobleman and military leader. Burgos is crossed by the Arlanzón River, adding to its picturesque scenery. The city is a significant stop on the Camino de Santiago, attracting thousands of pilgrims yearly. Additionally, Burgos is known for its culinary specialties, including Morcilla de Burgos, a type of blood sausage.

  • CT-EU-00118687

    Long-term safety and efficacy study of PTC518 for Huntington’s disease

    This study focuses on Huntington’s Disease and evaluates the long-term safety and effectiveness of the drug PTC518. Participants, who have previously completed related study phases, will continue taking PTC518 in doses of 5, 10, or 20 milligrams. The study aims to monitor the safety of long-term use and assess how the drug impacts biological markers and symptoms of the disease over a period of 30 months. This is an extension study where all participants will receive the active drug, ensuring continuous monitoring and evaluation of its effects.

    • PTC518
  • Studying rilzabrutinib for chronic immune thrombocytopenia

    The research is underway to evaluate the efficacy and safety of a medication called rilzabrutinib in adults and teenagers with Immune Thrombocytopenia (ITP), a chronic blood condition characterized by a low platelet count. Participants will receive either the medication or a placebo twice daily over a period of about a year and a half. Platelet levels, overall health, and quality of life will be measured before and during the study to gather comprehensive data.

    • Rilzabrutinib
  • A clinical trial evaluating Tominersen in the treatment of early stages of Huntington’s disease

    This clinical trial is focused on evaluating the investigational drug, tominersen, in people in the early stages of Huntington’s disease, a genetic disorder characterized by the progressive loss of nerve cells in the brain.

    The aim of this study is to understand the potential of tominersen to slow the progression of the disease and improve quality of life by administering different doses of this drug or a placebo directly into the spinal cord to reach the areas of the brain most affected by the disease. Participants’ health will be closely monitored and a series of assessments will be conducted to track changes in motor function, cognitive abilities and emotional well-being. Additionally, the study will measure specific biomarkers to assess the biological impact of treatment, offering valuable information for tailoring future therapies. This study provides an important opportunity to better understand Huntington’s disease and explore effective treatment options.

    • Placebo
    • Tominersen
  • Testing new medication for safety and effect on Huntington’s disease

    This study focuses on Huntington’s Disease and evaluates the safety and effectiveness of the drug PTC518. Participants will be randomly assigned to different groups based on their disease stage and will receive either PTC518 in varying doses (5 mg, 10 mg, or 20 mg) or a placebo. The study’s main aim is to observe the drug’s safety and its effects on disease-related proteins and brain changes over 12 months.

    • PTC518- new potential medication for Huntington’s disease
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • New hepatocellular carcinoma treatment study: evaluating a combination of atezolizumab, bevacizumab, and tiragolumab

    This clinical trial is focused on patients with untreated, advanced liver cancer, known as hepatocellular carcinoma (HCC). It aims to determine the effectiveness and safety of a new treatment combination. The trial involves two main drugs, atezolizumab and bevacizumab, and tests the addition of a third drug, tiragolumab, for some participants. These medications are given intravenously every three weeks. The trial is designed as a randomized, double-blind study, meaning participants are randomly assigned to different treatment groups without knowing which treatment they receive. The study will measure how long patients live without the disease getting worse (progression-free survival) and overall survival. It will also assess the response rate to the treatment, how long the response lasts, and any side effects. Additionally, the trial evaluates the participants’ quality of life and monitors drug concentrations in the blood. This study is significant for patients with HCC, offering a potential new treatment option that could improve their outcomes and quality of life.

    • Bevacizumab
    • Atezolizumab
    • tiragolumab
  • CT-EU-00036742

    Monitoring RSV vaccine safety in post-vaccination pregnancies

    This study tracks the safety of the RSVPreF3 vaccine in women who had it during previous pregnancies. It’s focused on women who are pregnant again after receiving the vaccine and will assess the health of both mothers and their babies. The study’s main aim is to understand any potential impacts of the vaccine on pregnancy outcomes and infant health. This research is important as it provides vital information on the safety of RSV vaccines in pregnant women, contributing to public health knowledge.

  • Continuation of sodium zirconium cyclosilicate (SZC) therapy in patients with kidney diseases after hospitalization

    This clinical trial investigates the use of sodium zirconium cyclosilicate (SZC) in patients with chronic kidney disease (CKD) treated for hyperkalaemia (high potassium levels) in the hospital. The study compares continuing SZC treatment after discharge with standard care to see if SZC is better at maintaining normal potassium levels and reducing hospital visits. It’s open to adults with CKD and hyperkalaemia. The trial aims to improve post-discharge care and reduce health resource use in these patients.

    • Sodium Zirconium Cyclosilicate (SZC)
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in Spain:

.